More than 5 million Americans have been diagnosed with RLS and as many as 1 in 10 adults will experience symptoms of RLS in their lifetime. Atlanta-based NeuroTrials Research is currently conducting a clinical research study of an investigational medication to treat Restless Legs Syndrome (RLS).
The primary symptom of RLS is an irresistible urge to move limbs in order to relieve uncomfortable sensations which can be severe at times. While the disorder most commonly affects legs, it can also be experienced in the arms or torso. The constant need to move causes difficulty falling asleep or patterns of interrupted and restless sleep. Common symptoms include:
- Creepy crawly sensations in the legs or arms, especially when at rest
- Uncomfortable sensations may be relieved by rubbing or moving around
- Discomfort begins in the early evening and intensifies as bedtime approaches
Currently, NeuroTrials is evaluating a medication for the treatment of RLS that is already approved as a treatment for pain in Europe. If approved, this drug may be an alternative to some of the existing medications that carry varying levels of side effects.
“RLS is an underdiagnosed condition for which we need better options and we are excited to continue moving RLS research forward,” said Dr. Michael Lacey, Lead Investigator of the study at NeuroTrials, “RLS does not discriminate – it can begin at any age – and current treatment options come with a variety of side effects.”
Nationally recognized physicians and researchers founded NeuroTrials over a decade ago. NeuroTrials continues to attract important Phase I-IV studies that impact the health and welfare of residents in Atlanta and nationwide.
NeuroTrials is currently enrolling participants for this study. Patients who are 18-70 with a history of RLS for over 6 months, can contact NeuroTrials at 404-851-9934 for more information. Qualified study participants receive free medical evaluations, treatment and are compensated for their time and travel. For full study details, visit www.neurotrials.com/studies.aspx.